Ongoing Phase II trials for pediatric high-grade gliomas (pHGG) are exploring various agents, including nimotuzumab (NCT03620032, NCT04532229, NCT00561873, NCT00600054), erlotinib (NCT00418327), and cetuximab (NCT01884740), both as monotherapies and in combination with mTOR inhibitors. Here, MTOR is linked to malignant glioma.